A phase II trial of girentuximab in combination with low-dose interferon alpha-2a in patients with metastatic clear cell renal cell cancer.
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2006
At a glance
- Drugs Girentuximab; Interferon alpha-2a
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors WILEX AG
- 19 Oct 2006 New trial record.